title: [Therapeutics of Burkitt lymphoma in adults - review].
abstract: Burkitt lymphoma is a highly aggressive non-Hodgkin's lymphoma. As Burkitt lymphoma cells are very sensitive to chemotherapy, chemotherapy is the major therapeutic schedule for this disease. Rituximab raised the overall survival rate markedly. Bone marrow transplant, surgery and radiotherapy also demonstrated to have a supporting role for patients with Burkitt lymphoma. This review focus on research progress of the therapeutics and major regimens for the disease.
authors.affiliation: Department of Hematology (Key Medical Discipline), Zhongda Hospital, Southeast University Medical School, Nanjing, Jiangsu Province, China.
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Bao-An
authors.initials: BA
authors.lastname: Chen
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab